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Abstract
Lipid-based oil-filled nanoparticles (NPs) with a high concentration of surface-chelated nickel
(Ni-NPs) were successfully prepared using a Brij78-NTA-Ni conjugate synthesized with Brij 78
(Polyoxyethylene (20) stearyl ether) and nitrilotriacetic acid (NTA). The facile incorporation of
the Brij 78-NTA-Ni conjugate into the NP formulation allowed up to 90% Ni incorporation, which
was a significant improvement over the previously used standard agent DOGS-NTA-Ni which led
to ~6% Ni incorporation. The Ni-NPs were targeted to the highly epidermal growth factor receptor
(EGFR)-overexpressing epidermoid carcinoma cells A431. This was accomplished using a novel
high affinity histidine×6-tagged EGFR-binding Z domain (heptameric ZEGFR domain). In vitro
cell uptake studies showed enhanced internalization (up to 90%) of the targeted Ni-NPs in A431
cells with only ≤10% internalization of the of untargeted Ni-NPs. ICP-MS analysis used to
quantify the amount of Ni in the cells were in close agreement with flow cytometry studies, which
showed a dose dependent increase in the amount of Ni with the targeted Ni-NPs. Cell uptake
competition studies showed that internalization of the targeted Ni-NPs within the cells was
competed off with free heptameric ZEGFR domain at concentrations of 8.75 ng/mL or higher. In
vivo studies were carried out in nude mice bearing A431 tumors to determine the biodistribution
and intracellular delivery. Near Infrared (NIR) optical imaging studies using Alexa750-labeled
heptameric ZEGFR domain showed localization of 19% of the total detected fluorescence intensity
in the tumor tissue, 28% in the liver and 42% in the kidneys 16 h post i.v. injection. ICP-MS
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analysis showed almost a two-fold increase in the amount of intracellular Ni with the targeted Ni-
NPs. These new Ni-NPs could be a very useful tool for targeting and drug delivery to a wide range
of EGFR positive cancers.
Keywords
lipid-based nanoparticles; nickel; histidine-tagged proteins; EGFR targeting; heptameric ZEGFR
domain
Introduction
One of the major requirements for a successful cancer therapeutic is the ability to selectively
kill cancer cells with minimal damage to healthy tissue. Selective delivery of
chemotherapeutics to cancer cells is an approach known as molecular targeted therapy. This
technique is currently combined with chemotherapy and has the potential to replace it in the
future.[1] The principle behind targeted therapy is to utilize molecules that interfere with the
development and growth of cancer. Amongst these molecules, the human epidermal growth
factor receptor (EGFR) has emerged as an attractive target for cancer therapy. The EGFR is
a transmembrane tyrosine kinase receptor that regulates important cellular processes such as
cell proliferation, apoptosis, differentiation and migration.[2] Overexpression of EGFR has
been detected in a wide range of cancers including breast, ovarian, bladder, head and neck,
glioma, pancreatic, kidney, lung and prostate, making it an attractive target for both
therapeutic and diagnostic applications.[3-5] In the past decade, several EGFR-targeted
anticancer therapeutics have been developed using either monoclonal antibodies (MAbs;
cetuximab,[6] panitumumab[7]) or tyrosine kinase inhibitors (TKIs; gefitinib[8],
erlotinib[9], lapatinib[10]) to block uncontrolled EGFR-mediated signaling.[11-13] More
recently, a new class of affinity proteins known as affibody molecules have been introduced
as an alternative approach to antibodies for EGFR-targeted systems.[14, 15] Affibodies are
comprised of 58 amino acid residues bundled in a three-helix scaffold, a structure derived
from the Z-domain of staphylococcal protein A.[16] Additionally, affibody molecules are
small (~7 kDa) and are easy to produce by recombinant production in bacteria or by
chemical synthesis.[17] Moreover, these proteins have a very high affinity for different
receptors including EGFR, HER2, HER3 and HER4.[18, 19] Affibody proteins have been
extensively investigated as in vivo imaging agents because of their relatively small size, their
ability to exhibit fast tumor targeting, high tumor uptake, and quick clearance from normal
tissue.[20-22] In addition, their high binding affinity to EGFR makes them a very appealing
targeting ligand for the delivery of therapeutic agents to a wide range of EGFR-
overexpressing cancer cells.[23]
To further enhance the binding efficiency, Liu et al. generated a heptameric EGFR-binding
targeting ligand, by fusing a heptamerization domain with an EGFR-binding Z domain. The
resulting heptameric targeting ligand is highly stable, can withstand SDS denaturing and
binds to EGFR-expressing cancer cells with a significantly improved binding affinity. In
vitro cell binding studies showed that as low as 0.1 nM of heptameric ZEGFR (125 kDa)
bound to EGFR-positive A431 cells tightly and specifically, whereas more than 100 nM
monomeric ZEGFR (18 kDa) was required to achieve similar results (unpublished results).
The targeting ligand can be terminated with a histidine×6-tag for site-specific attachment to
various drug delivery systems such as liposomes and nanoparticles via his-tag-Ni affinity
binding.[24] This approach has several advantages over the use of covalent linkages
including, facile attachment, mild conditions and the ability to achieve site specific and
oriented attachment and high coupling efficiencies.[25-27]
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In the present studies, the surface of Ni-loaded NPs was decorated with a his×6-tagged
heptameric ZEGFR domain to target EGFR-overexpressing human epidermoid carcinoma
A431 cells. In order to achieve tight association between the his×6-tagged protein and the
surface of the NPs, two different NTA-derivatized Brij surfactants (Brij 78-NTA and Brij
700-NTA) were synthesized and then used to prepare the lipid-based NPs. The synthesis of
the new conjugates was simple and high yielding. Using these new conjugates, a significant
increase (>10-fold) in Ni incorporation was achieved compared to previous results using the
commercially available DOGS-NTA-Ni.[28] More importantly, the delivery of the EGFR-
targeted Ni-NPs using the novel his×6-tagged heptameric ZEGFR domain was accomplished
in vitro and in vivo in A431 cancer cells. Combined, these results show a great potential for
the novel heptameric ZEGFR domain as a targeting ligand to facilitate the delivery and
accumulation of nanocarriers to various EGFR overexpressing tumor tissues. To our
knowledge, this is the first report on the development of Ni-NPs using Brij 78-NTA-Ni




1.1. Chemicals—Polyoxyethylene (20) stearyl ether (Brij 78) was purchased from
Uniqema (Wilmington, DE). D-alpha-tocopheryl polyethylene glycol 1000 succinate
(TPGS) was purchased from Eastman Chemicals (Kingsport, TN). Miglyol 812 is a mixed
caprylic (C8:0) and capric (C10:0) fatty acid triglyceride and was purchased from Sasol
(Witten, Germany). TEMPO free radical (98%), iodobenzene diacetate (98%), N-
hydroxysuccinimide (NHS) and nitrilotriacetic acid (NTA, 97+%) were purchased from
Sigma Aldrich (Milwakee, MI). 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide
hydrochloride (EDC, 98+%) was purchased from Alfa Aesar (Ward Hill, MA). Nickel
chloride hexahydrate was purchased from Fisher Scientific (City, State). Acetonitrile
(CH3N), dichloromethane (CH2Cl2), tetrahydrofuran (THF), ethanol (EtOH), and diethyl
ether were purchased from Fisher Scientific.
1.2. Cells—A431 epidermoid carcinoma cells (American Type Culture Collection,
Rockville, Maryland) were used as a model cell for their very high levels of epidermal
growth factor receptor (EGFR) expression. Prior to cell uptake studies, A431 cells were
cultured in Dulbecco’s Modified Eagle Medium, high glucose (DMEM, Invitrogen™, Grand
Island, NY, USA) supplemented with 10% fetal bovine serum (FBS, Mediatech Inc.,
Manassas, VA, USA) and 1% penicillin streptomycin solution (Pen Strep, Invitrogen™,
Grand Island, NY, USA) at 37°C and 5% CO2.
1.3. Analysis—Optical microscopy analysis of cells were carried out using a Zeiss
Invertoskop 40C Optical Microscope. Cells (10,000 per sample) were analyzed by flow
cytometry (CyAn ADP, Dako), for green and red fluorescence. In vivo fluorescence imaging
studies were carried out using the IVIS® spectrum (Caliper Life Sciences) with an epi-
illumination (from the top) capability to illuminate in vivo fluorescent sources.
1.4. Characterization
1.4.1. NMR: NMR spectra were measured on Varian 400 MHz spectrometer. 1H spectra
were recorded at 400 MHz, and 13C NMR spectra were recorded at 100 MHz in CDCl3 or
CD3OD. The non-deuterated solvent signal was used as internal standard for both 1H
and 13C spectra.
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1.4.2. ICP-MS: Inductively Coupled Plasma Mass Spectrometry (ICP-MS) experiments
were conducted to quantify Ni content within the lipid-based nanoparticles using a Varian
820-ICPMS, Inductively Coupled Plasma Mass Spectrometer. The source had a MicroMist
nebulizer, max flow rate of 0.4 mL/min, for sample introduction into the plasma. Standard
plasma conditions (Power 1.4 kW, plasma flow 18.00 L/min, auxiliary flow 1.80 L/min,
sheath gas flow 0.18 L/min and sampling depth 7.5 mm) were used. All solutions were
prepared using 18 mega ohm de-ionized water (lab supply) and trace metal grade Nitric
Acid (Thermo Fisher Scientific Inc.). Instrument conditions were optimized using the auto-
optimization feature of this instrument. Samples were introduced while setting the peristaltic
pump at 3 rpm. The spray chamber was cooled to 3°C. Standards were prepared using ICP
standards purchased from Inorganic Ventures, Christiansburg, VA. In all measurements, a 5
ppb solution of Indium was used as internal standard and mixed online with each sample
through a tee. Ions In115 (internal standard), and 60Ni were monitored in a peak hopping
mode, using 50000 μSec as dwell time, and measuring 5 replicates of an average of 20 data
points. This gave a scan time of 359 msec and replicate time of 7.17 seconds. The Ni
standard curve included 9 to 13 concentration levels in the range of 0.1 to 500 ppb. The
standard data set was fitted to a linear curve. The coefficient of correlation was 0.999 or
higher in each of the several data sets. Percent Error in calculated concentrations was 11%
or lower (in most cases it was less than 5%). The blank equivalent was less than 0.1 ppb.
Only the test data greater than three times the blank equivalent (i.e. 0.3 ppb) were accepted
as valid measurement. During the analysis of each test sample, a reference sample was used
for validation and comparison of the test results. For quantitation of Ni in the NPs,
preparation included removing the water from the NPs and re-suspending them in 2% HNO3
solution. Cell samples with internalized Ni, from in vitro flow cytometry studies, involved
taking a 0.5 mL of each cell sample and diluting it with 2% HNO3 to a total volume of 3.0
mL. In the case of in vivo studies, tumor cells were extracted from homogenized tumors,
using a digestion mixture (described in section 2.6.1). The final cell pellet from this step was
re-suspended in 2% HNO3 to a total volume of 3.0 mL for analysis by ICP-MS.
1.4.3. NP characterization: Additional characterization techniques included particle size
measurement of the Ni-NPs using a Coulter N4 Plus Sub-Micron Particle Sizer (Coulter
Corporation, Miami, FL) at 90°, and zeta potential using a Malvern Zeta Sizer 2000
(Malvern Instruments, Southborough, MA).
2. Methods
2.1. Synthesis
General procedure for oxidation of Brij 78: Polyoxyl 20-stearyl ether (Brij 78) (MW =
1152 Da) (2.01 g, 1.74 × 10-3 mol, 1 equiv) was introduced to a round-bottom flask
equipped with a magnetic stir bar as a solution in a 1:1 mixture of water/acetonitrile (40
mL). TEMPO free radical (0.05 g, 3.47 × 10-4 mol, 0.2 equiv) was added to the solution,
followed by iodobenzene diacetate (1.68 g, 5.21 × 10-3 mol, 3 equiv). The reaction mixture
was stirred at room temperature for 6 h (or overnight to ensure the reaction went to
completion). The mixture was then concentrated to dryness in vacuo and the residue was
dissolved in a minimum amount of ethanol. The crude polymer was precipitated in cold
diethyl ether, and recovered by filtration through a glass fritted funnel. After drying in
vacuo, Brij 78-acid was obtained as a white solid (1.81 g, 90%). 1H NMR (400 MHz,
CD3OD): δ (ppm) = 0.9 (t, 3H, −CH3(CH2)16), 1.3 (s-broad, 30H, −(CH2)15 CH3), 1.56 (t,
2H, −CH2(CH2)15CH3), 3.46 (t, 2H, −CH2O), 3.63 (s-broad, 72H, −CH2CH2O), 4.1 (s, 2H,
−CH2 CO2H). 13C NMR (100 MHz, CD3OD): δ (ppm) = 13.1 (−CH3(CH2)15), 22.34
(−CH2CH3), 25.83 (−CH2CH2CH3), 29.36 (−(CH2)14CH2O), 67.98 (−CH2CO2H), 69.78
(−CH2O-CH2CO2H), 70.16 (−CH2CH2O), 70.96 (−(CH2)16CH2O), 172.93 (−CO2H).
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General procedure for synthesis of Brij 78-NHS active ester: A flame-dried round
bottom flask was charged with Brij 78-acid (1.05 g, 9.0 × 10-4 mol, 1 equiv) and dissolved
in dry THF (20 ml) under argon. 1-(3-Dimethylaminopropyl)-3-ethylcarbodiimide
hydrochloride (EDC) (0.34 g, 1.79 × 10-3 mol, 2 equiv) along with N-hydroxysuccinimide
(NHS) (0.21 g, 1.79 × 10-3 mol, 2 equiv) were added and the solution was stirred at room
temperature for 12 h. The precipitate was removed by filtration through a fritted funnel, and
the filtrate was concentrated by rotary evaporation. The filtered residue was redissolved in a
minimum amount of CH2Cl2 and passed through a fritted funnel to remove any residual
precipitate. The filtrate solvent was removed by rotary evaporation to give the desired
product as a white solid (1.03 g, 91%). 1H NMR (400 MHz, CDCl3): δ (ppm) = 0.85 (t, 3H,
−CH3(CH2)16), 1.23 (s-broad, 30H, −(CH2)15 CH3), 1.54 (t, 2H, −CH2 (CH2)15CH3), 2.83
(s, 4H, −CH2CON), 3.42 (t, 2H, −CH2O), 3.62 (s-broad, 72H, −CH2CH2O), 4.5 (s, 2H,
−CH2CO2H). 13C NMR (100 MHz, CDCl3): δ (ppm) = 14.08 (−CH3(CH2)15), 22.65
(−CH2CH3), 25.42 (−CH2CH2CH3), 26.06 (−CH2CON), 29.36 (−(CH2)14CH2O), 67.98
(−CH2CO2H), 69.78 (−CH2O-CH2CO2H), 70.16 (−CH2CH2O), 70.96 (−(CH2)16CH2O),
165.98 (−CON), 168.73 (−CO2H).
General procedure for the synthesis of Brij 78-NTA conjugate: Brij 78-NHS active ester
(0.51 g, 4.03 × 10-4 mol, 1 equiv) was introduced to a round-bottom flask equipped with a
magnetic stir bar as a solution in a mixture of CH2Cl2/H2O (5:1, 20 mL). Nitrilotriacetic
acid (NTA) (0.13 g, 4.83 × 10-4 mol, 1.2 equiv) was added, and the solution was stirred at
room temperature overnight. The solvent was removed by rotary evaporation and the solid
was dissolved in a minimum amount of CH2Cl2 to remove the NHS by-product. The solid
precipitate was removed by filtration through a fritted funnel and the filtrate solvent was
removed by rotary evaporation to give the desired product as a white solid: 0.58 g (98%). 1H
NMR (400 MHz, CDCl3): δ (ppm) = 0.81 (t, 3H, −CH3(CH2)16), 1.18 (s-broad, 32H, −
(CH2)16 CH3), 2.82 (s, 2H, −NCH2CO2H), 2.91 (s, 2H, −NCH2CO2H), 3.37 (t, 2H, −CH2-
NHCOCH2), 3.57 (s-broad, 72H, −CH2CH2O), 4.08 (s, 2H, −CH2CO2H). 13C NMR (100
MHz, CDCl3): δ (ppm) = 14.08 (−CH3(CH2)15), 22.65 (−CH2CH3), 26.04 (−CH2CH2CH3),
26.06 (−CH2CON), 29.6 (−(CH2)14CH2O), 30.3 (−CH2CH2NHCO), 36.7 (−CH2NHCO),
57.9 (−NCH2CO2H), 70.34 (−CH2CH2O), 71.51 (−OCH2CONH), 73.8 (−CHCO2H),
163.01 (−CONH), 174.3 (−CO2H).
General procedure for the synthesis of Brij 78-NTA-Ni conjugate: Brij 78-NTA (1.22g,
8.5 × 10-4 mol, 1 equiv) was introduced to a round bottom flask equipped with a magnetic
stir bar in DI water (50 mL), and the pH was adjusted to ~pH 8 with 1N NaOH (0.5 mL).
NiCl2.6H2O (0.4, 1.7 × 10-3 mol, 2 equiv) was added, and the solution was stirred at room
temperature overnight. The nickel-chelated conjugate was purified using a Zeba® desalting
column to remove the excess NiCl2. The percent chelation was quantified by ICP-MS
analysis in reference to the amount of Ni in the solution prior to purification.
General procedure for the synthesis of Brij 700-NTA-Ni: Brij 700-NTA-Ni was
synthesized following the same procedure outlined above for Brij 78-NTA-Ni.
2.2. Formulation of Ni-NPs
General procedure for the preparation of Ni-NPs using Brij 700-NTA-Ni: Nanoparticles
were prepared from warm oil/water (o/w) microemulsion precursors following a previously
reported procedure.[29] In the optimized formulation, Brij 78 (2.9 mg), TPGS (1.5 mg),
Miglyol 812 (2.5 mg), and Brij 700-NTA-Ni (0.6 mg, 8wt.%) were weighed into a 7 mL
glass vial and heated in a water bath to 65°C to melt and blend the excipients. A small
amount of ethanol (100 μL) was added to the melted excipients and the solution was swirled
to help form a homogenous mixture. The ethanol was removed completely using a stream of
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nitrogen and the vial was transferred to a water bath at 65°C. “One (1) mL of filtered and
deionized (D.I.) water pre-heated at 65°C was added into the mixture of melted oil and
surfactants, and the solution was stirred for 30 min at 65°C then cooled to room temperature.
General procedure for the preparation of Ni-NPs using Brij 78-NTA-Ni: Nanoparticles
were prepared from warm o/w microemulsion precursors as described above with some
modification. In the optimized formulation, Brij 78 (0.7 mg), Brij 78-NTA-Ni (2.8 mg),
TPGS (1.5 mg), and Miglyol 812 (2.5 mg) were weighed into a 7 mL glass vial and heated
in a water bath to 65°C to melt and blend the excipients. A small amount of ethanol (100
μL) was added to the melted excipients and the solution was swirled to help form a
homogenous mixture. The ethanol was removed completely using a stream of nitrogen and
the vial was transferred to a water bath at 65°C. “One (1) mL of filtered and deionized (D.I.)
water pre-heated at 65°C was added into the mixture of melted oil and surfactants, and the
solution was stirred for 30 min at 65°C then cooled to room temperature.
2.3. Optimization of histidine×6-tagged green fluorescent protein (his-tag
GFP) binding to Ni-NPs—Briefly, 500 μL of Ni-NPs was passed down a Sepharose
CL-4B size exclusion chromatography (SEC) column (15 × 100 mm) column using PBS, pH
7.4 as a mobile phase. Fractions (1 mL) were collected and those containing NPs (as
determined by dynamic light scattering measurement of particle size) were combined and
used for binding his×6-tagged GFP. Binding studies of his×6-tagged GFP to Ni-NPs
prepared with Brij 700-NTA-Ni were carried out using optimal binding conditions at a ratio
of 0.0045 w/w his×6-tagged GFP to Ni-NPs. The Ni-NPs were incubated with the
corresponding amount of his×6-tagged GFP in PBS, pH 7.4 at 4°C overnight. Free his×6-
tagged GFP was removed by a Sepharose CL-4B SEC column (15 × 70 mm) with PBS, pH
7.4 as the mobile phase. Fractions 1-24 (1 mL) were collected and analyzed by fluorescence
spectroscopy to determine the percent of his×6-tagged GFP bound to the Ni-NPs. The
fluorescence was measured using a BioTek Synergy 2 Fluorescence Spectrometer
(Winooski, VT) with excitation and emission wavelengths set at 494 and 518 nm,
respectively.
2.4. Optimization of his×6-tagged heptameric ZEGFR domain binding to Ni-NPs
—The Ni-NPs prepared with Brij 78-NTA-Ni were purified as described above and
incubated with FITC-labeled heptameric ZEGFR domain at 2.5, 3.5, 5.0, 10 and 15 μg liagnd/
1500 μg Ni-NPs to determine the optimal binding conditions. Unbound targeting ligand was
separated by SEC column using PBS, pH 7.4 as the mobile phase. Fractions 1-24 (1 mL)
were collected and analyzed by fluorescence spectroscopy to determine the percent of his×6-
tagged FITC-labeled heptameric ZEGFR domain bound to the Ni-NPs. The fluorescence was
measured with excitation and emission wavelengths set at 494 and 516 nm, respectively.
2.5. In vitro cell uptake studies—The EGFR-overexpressing A431 cell line was used to
investigate the uptake of EGFR-targeted Ni-NPs. A431 cells (passage 3) were cultured
under standard conditions (37°C, 95% relative humidity, 5% CO2 in Dulbecco’s Modified
Eagle Medium, high glucose (DMEM) supplemented with 10% fetal bovine serum (FBS)
and 1% penicillin/streptomycin). For cell uptake experiments, the confluent cells were
trypsinized and centrifuged using a Beckman Coulter, Allegra™ X-12R Centrifuge at 900
rpm for 5 min. The resulting cell pellet was re-suspended in the required amount of
complete medium (DMEM) to achieve a cell-plating density of 20,000 cells per mL of
medium. The cells were plated into 24-well tissue culture flat bottom plates (Corning/Costar
3526) and allowed to incubate overnight to about 40-50% confluency. The following day,
untargeted and EGFR-targeted Ni-NPs were diluted in complete medium to obtain a final
assay concentration of 1, 5, and 15 μg/mL. NPs (300 μL) were then incubated with cells
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over a time course ranging from 15 min to 4 h (37°C, 5% CO2). After cell/NPs incubation,
the cells were washed with 1× Dulbecco’s Phosphate Buffered Saline solution (D-PBS) and
detached by trypsinization (300 μL/well). Cells were resuspended in a 1:1 solution of 0.4%
trypan blue (TB) solution in 1× D-PBS containing 10% FBS (500 μL/well; total sample
volume 800 μL) and transferred to a 5 ml Falcon (352063) polypropylene round-bottom
tube. This assay relies on the observation that the FITC-label of non-internalized particles
acquires red fluorescence while losing its green fluorescence when incubated with the vital
dye TB. Internalized particles on the other hand will fluoresce green.[30] Cells (10,000 per
sample) were analyzed by flow cytometry (CyAn ADP, Dako), for green and red
fluorescence.
2.6. In vivo studies—Female nude athymic (nu/nu) mice, 4 to 6 wk (Harlan
Laboratories), were housed in a pathogen-free room. All experiments involving the mice
were carried out with an approved protocol by the University of North Carolina Animal
Care and Use Committee. The mice were injected s.c. in the right flank region with 2 × 106
A431 cells suspended in DMEM. Tumors were measured in two perpendicular dimensions,
and tumor volume was calculated using the formula V = (L × W2)/2, where L and W are the
longest and shortest diameters, respectively. When the tumors reached volumes between
300-500 mm3, the mice were randomly divided into three groups, a naïve group, a group
injected with untargeted Ni-NPs and a third group injected with EGFR-targeted Ni-NPs
using his×6-tagged, Alexa750-labeled heptameric ZEGFR domain. Mice were injected with
Ni-NPs in 200 μL of isotonic saline solutions via intravenous (i.v.) injection.
2.6.1. Intracellular tumor cell analysis of delivered Ni by ICP-MS: To evaluate the
efficacy of the heptameric ZEGFR domain in targeting Ni-NPs, Ni concentrations within cells
extracted from tumor homogenates were quantified by ICP-MS analysis. The mice were
euthanized and the tumors were harvested and transferred to a solution of phosphate
buffered saline (PBS, 5 mL) containing Fungizone (0.01%) and Penstrep (0.01%). The
tumors were then transferred to a 50 mL Falcon tube containing 5 mL of complete DMEM,
and homogenized using a Tissue Tearor™ (Biospec products, Inc.) homogenizer. To
dissociate single cells from tumor fragments, 20 mL of tumor digestion enzyme mixture
(Hyaluronidase, Type V; Collagenase, type IV and DNase, Type IV, Sigma Aldrich) was
added to the medium containing the cell homogenate, and the solution was mixed
thoroughly followed by incubation for 3 h at 37°C with periodical mixing every 10-15 min.
The cell homogenate solution was passed first, through a 70 μm sterile mesh filter, and a
second time through a 40 μm sterile filter to ensure removal of any large undigested tumor
fragments. The filtrate was centrifuged (Thermo IEC CL40R centrifuge) at 1100 rpm for 5
min. The resulting cell pellet was re-suspended in 9 mL of 1× Osmotic Lysis Buffer for 30
sec with continuous mixing to remove any red blood cells (RBC) contaminant. The cell
suspension was centrifuged at 1100 rpm for 5 min, and the resulting cell pellet was re-
suspended in lysis buffer for 15 min at room temperature. Finally, the cell suspension was
centrifuged at 1100 rpm for 5 min, and the resulting cell pellet was rinsed twice with Hank’s
buffer salt solution (HBSS, 5 mL). The cell pellet was re-suspended in HBSS (0.5 mL) and
2% nitric acid (2.5 mL) for ICP-MS analysis to quantify intracellular Ni accumulation
within the tumor homogenate. 2% nitric acid was used for digestion and solubility purposes
for ICP-MS analysis.
2.6.2. In vivo optical imaging: Fluorescence imaging studies were carried out 16 h post i.v.
injection, using the IVIS® Spectrum (Caliper Life Sciences) with an epi-illumination (from
the top) capability to illuminate in vivo fluorescent sources. Two weeks prior to i.v.
injection, the mice were kept under alfalfa-free diet to minimize background fluorescence
from the food. The heptameric ZEGFR domain was labeled with Alexa750 and conjugated to
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the Ni-NPs via noncovalent Ni- his×6-tag affinity binding. The mice were anesthetized
using isoflurane and transferred to the IVIS instrument to collect full body images (Ex. 745
nm and Em. 800 nm). The mice were given an overdose of ketamine and domitor to deeply
anesthetize them prior to cardiac puncture to collect blood, and a cervical dislocation was
then performed to euthanize the mice. The organs/tumors were harvested and transferred to
12-well plates and imaged using IVIS at 30 sec scanning time. Tumors and organs were
weighed and percent fluorescence was qualitatively evaluated based on the total
fluorescence detected from all organs, tumors and blood.
Statistical Analysis
Statistical analysis was performed using one-way analysis of variances (ANOVA) followed
by pair-wise comparisons using Tukey’s multiple comparison test using GraphPad Prism
Software (©1992-2007 GraphPad Prism Software, Inc). Results were considered significant
at 95% confidence interval (p<0.05).
Results and Discussion
Synthesis
Brij 700-NTA-Ni and Brij 78-NTA-Ni conjugates were prepared using the same synthetic
strategy. For Brij 700-NTA-Ni, this was accomplished by first converting the terminal
hydroxyl group of polyoxyl 100-stearyl ether (Brij 700) to a carboxylic acid group using the
TEMPO-mediated oxidation.[31] The carboxylic acid derivative (2) of Brij 700 was
subsequently reacted with excess N-hydroxysuccinimide (NHS) and 1-(3-
Dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDC). The resulting NHS-
active ester of Brij 700-acid (3) was subsequently reacted with nitrilotriacetic acid (NTA) to
give Brij 700-NTA conjugate. The chelation of nickel to Brij 700-NTA (4) was carried out
using excess NiCl2.6H2O to obtain the final conjugate (Scheme 1).[32] The excess NiCl2
was removed using a Zeba desalting column and the purified conjugate was analyzed by
inductively coupled mass spectrometry (ICP-MS) analysis to quantify the amount of Ni
chelated to the NTA head group of the Brij 700-NTA conjugate. Results from ICP-MS
analysis showed that the ratio of Brij 700- NTA to Ni was close to 1:1 after purification with
a Zeba desalting column indicating near quantitative yields (Table 1).
Optimization of BTM-Ni NPs formulation using Brij 700-NTA-Ni
The preparation of Niloaded BTM NPs (Ni-NPs) can be carried out in a number of ways,
including (a) the use of the commercially available DOGS-NTA-Ni conjugate which can be
incorporated into the lipid core of the BTM NPs, (b) the use of Brij 700-NTA-Ni
synthesized from Brij 700 previously added as a pegylation agent for the original BTM NPs
formulation, (c) the use of Brij 78-NTA-Ni synthesized from Brij 78, the main surfactant
component in the BTM NP formulation. Previous studies in our lab showed that the use of
DOGS-NTA-Ni to incorporate Ni in lipid-based NPs resulted in very little Ni incorporation
(<10%).[28] This is thought to be due to the hydrophobic nature of DOGS-NTA, which
presumably incorporates within the NPs but limits accessibility of Ni to the surface of the
NPs. This limitation can be addressed by conjugating the NTA-Ni head group to a molecule
that would have both a hydrophilic chain to promote accessibility of Ni to the surface of the
NPs, and a hydrophobic chain that would enhance incorporation of the conjugate within the
lipid core of the NPs. To do this, a novel Brij 700-NTA-Ni conjugate was successfully
synthesized using Brij 700. When Brij 700 was added as a PEGylating agent in the BTM NP
formulation, the optimal amount was determined at 8% w/w (Brij 700 to Miglyol 812).[33]
Based on these findings, optimization of the new BTM-Ni NP formulation was carried out
using various amounts of Brij 700-NTA-Ni conjugate ranging from 0.5-8% w/w (Brij 700-
NTA-Ni to total NP) (Table 2). The Ni-NPs were characterized by measuring their particle
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size and zeta potential, and by ICP-MS analysis to quantify the percent Ni associated with
each NP composition. The Ni-NPs had a mean size of ~190 nm and exhibited an increasing
negative charge with increasing Ni content ranging from -12 mV to -22 mV (Table 3).
Incorporation efficiency of Brij 700-NTA-Ni in NPs based on Ni content
The concentration of Ni in the various NP formulations was quantified by ICP-MS analysis.
Prior to analysis, the Ni-NPs were purified by size exclusion chromatography (SEC) using a
Sepharose CL-4B packed column to isolate NPs within the 200 nm range. Both unpurified
and purified Ni-NPs were transferred to individual 15 mL Falcon tubes and diluted with 2%
nitric acid (10 mL) for analysis. The percent Ni incorporation in the purified Ni-NPs was
calculated in reference to the original Ni concentrations of the unpurified Ni-NPs. ICP-MS
analysis showed a significant increase in Ni incorporation within the NPs (32-48%, Table 4)
compared to much lower incorporation efficiency (6-7%) previously obtained with DOGS-
NTA-Ni.[34] Results also indicated that increasing Brij 700-NTA-Ni content beyond 2% w/
w did not seem to further increase the incorporation efficiency of Ni within the NPs. This is
likely due to an equilibrium factor between Brij 78 and Brij 700-NTA-Ni since the original
amount of Brij 78 was reduced accordingly to compensate for the addition of Brij 700-NTA-
Ni and keep the total amount of surfactants constant in the NP formulation (Table 2).
Consequently, beyond a certain percent of Brij 700-NTA-Ni, a saturation point is reached,
which makes incorporation within the NPs more difficult, resulting in a plateau at ~50% Ni
incorporation (Table 4). However, the main goal of the present work was to design a system
with a high Ni content but also with an incorporation efficiency that was close to
quantitative in order to avoid extra purification steps to remove free NTA-Ni conjugate.
Binding efficiency of his×6-tagged GFP to the Ni-NPs
Based on the promising Ni incorporation results obtained with Brij 700-NTA-Ni, further
work to evaluate binding efficiency of the Ni-NPs to his×6-tagged proteins was carried out
using his×6-tagged GFP as a model protein. The Ni-NPs were incubated with his×6-tagged
GFP at a previously optimized ratio (data not shown) of 0.0045 w/w his-GFP to NPs at 4°C
overnight. SEC was used to separate unbound his×6-tagged GFP, and fractions (1 mL) 1-24
were collected and analyzed by fluorescence spectroscopy to determine the amount of
fluorescence associated with the NPs fractions (4-7). The binding efficiency of his×6-tagged
GFP to the Ni-NPs was ~55% based on the percent fluorescence associated with the NPs
fractions (~2.46 μg GFP/mg NPs). Surprisingly, these values were comparable to the
binding efficiency of his-GFP to Ni-NPs prepared with DOGS-NTA-Ni (~48%, 2.19 μg
GFP/mg NPs) (Table 5). Given the 8-fold increase in Ni incorporation using Brij 700-NTA-
Ni, these results suggested that the binding efficiency of his×6-tagged GFP to Ni-NPs was
not proportional to the amount of Ni within the NPs alone. It was hypothesized that, the low
binding efficiency of his×6-tagged GFP to the Ni- NPs was due to two reasons: 1) high
chain dynamics and mobility in water of the long PEG chain (PEG MW = 4 kDa, Brij 700-
NTA-Ni) induced protein repulsion,[35, 36] therefore hindering his-GFP binding to the Ni-
NPs, 2) An equilibrium phenomenon, which favors Brij 700-NTA-Ni to be in the aqueous
environment surrounding the NPs rather than its incorporation within the lypophilic core of
the NPs. To test these hypotheses, an intermediate conjugate between the fully lypophilic
DOGS-NTA-Ni and Brij 700-NTA-Ni with the long PEG chain was synthesized. This was
accomplished using polyoxyl 20-stearyl ether (Brij 78) (MW = 1152 Da), the main
surfactant in the BTM NP formulation, which differs from Brij 700 only in the length of the
PEG chain (Mw = 4400 Da for Brij 700 versus Mw = 880 Da for Brij 78).
Optimization of Ni-NP formulation for binding to his×6-tagged GFP using Brij 78-NTA-Ni
Synthesis of Brij 78-NTA-Ni was carried out following the same synthetic steps used to
make Brij 700-NTA-Ni conjugate (Scheme 1). In this new formulation, 50 wt.% of Brij 78
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in the original BTM NP formulation[37] was substituted with Brij 78-NTA-Ni. The percent
incorporation of Ni using Brij 78-NTA-Ni was significantly higher, where 89% of the
original Ni amount was associated with the NPs fraction as determined by ICP-MS analysis
(Table 5). The structural similarity of Brij 78-NTA-Ni and Brij 78, the main surfactant in the
NPs formulation, allowed incorporation of greater amounts (up to 80 wt.%) of Brij 78-NTA-
Ni in the NPs formulation resulting in enhanced Ni incorporation. This was not the case with
Brij 700-NTA-Ni, where the optimal amount that could be added to the NPs formulation
was 8 wt.%. These results were extremely promising in that being able to achieve nearly
quantitative Ni incorporation with Brij 78-NTA-Ni allowed for the development of a
formulation that can readily be used for in vitro and in vivo studies. Moreover, when
increasing the amount of Brij 78-NTA-Ni to 80% w/w (Brij 78-NTA-Ni to Brij 78), there
was no significant enhancement in the percent Ni incorporation (90%) within the NPs. This
suggested that increasing the amount of Brij 78-NTA-Ni beyond 50% w/w did not further
enhance percent Ni incorporation within the NPs.
Binding studies of his×6-tagged GFP to this new Ni-NPs formulation were carried out using
the aforementioned optimal binding conditions (0.0045 w/w his×6-tagged GFP to Ni-NPs).
Fluorescence analysis of SEC fractions showed a significant enhancement in binding
efficiency (~85%, 3.83 μg GFP/mg NPs) compared to previous results obtained with Brij
700-NTA-Ni based NPs (~55%, ~2.46 μg GFP/mg NPs) (Table 5). These results support our
hypothesis that by shortening the length of the PEG segment on the NTA-Ni conjugate,
enhanced Ni incorporation and binding efficiencies to a his×6-tagged protein were observed.
Based on these results, optimization studies for binding of a novel his×6-tagged heptameric
ZEGFR domain to the new Ni-NPs to target them to EGFR-overexpressing cancer cells were
carried out.
Optimization of FITC-labeled his×6-tagged heptameric ZEGFR domain binding to the Ni-NPs
One of the main limitations of coupling proteins to carriers using a noncovalent his-tag-Ni
interaction is the potential disruption of the his-Ni-NTA association in vivo. Szoka et al.
showed that while increasing the retention of his×6-tagged proteins to multivalent NTA
headgroups in vitro, this association was not robust enough in vivo.[38] In the present work,
we investigated the potential improvement of the his-tag-Ni-NTA association in vivo using a
multi-his×6-tagged protein (heptameric ZEGFR domain) to bind to a NP system that exhibits
high Ni content and improved Ni accessibility to the his×6-tagged protein.
The high affinity (Kd = 29 pM) heptameric ZEGFR domain was prepared by fusing a
heptamerization domain with an EGFR-binding Z domain. This process allowed for the
formation of a highly stable heptameric structure, without formation of other multimeric
intermediates. The targeting ligand was terminated with a his×6-tag to allow for site-specific
attachment to Ni-NPs via Ni-his-tag affinity binding.
Binding studies were accomplished using FITC-labeled heptameric ZEGFR domain (FITC-
his×6-tagged heptamer) at various FITC-his-heptamer to Ni-NPs w/w ratios to determine the
optimal conditions. SEC followed by fluorescence analysis showed that a binding ratio of
0.002 w/w (his×6-tagged-heptamer to Ni-NPs) or lower yielded binding efficiencies >90%
(Fig. 1, Table 6). These optimization studies were particularly important in minimizing
purification steps required to separate unbound protein from NP-bound protein prior to in
vitro and in vivo studies. Based on these results, in vitro and in vivo studies were completed
with the optimal binding conditions of 0.002 w/w his×6-tagged-heptamer to Ni-NPs ratio.
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Facilitated in vitro cell uptake of EGFR-targeted Ni-NPs in EGFR+ cancer cells
In vitro cell uptake studies were carried out to determine the percent internalization of the
targeted Ni-NPs in EGFR overexpressing epidermoid carcinoma cells, A431. Dose and time
dependency of cell uptake was investigated at Ni-NPs concentrations of 1, 5 and 15 μg/mL
and three time points (15min, 1h and 4h). Cell uptake was quantified by flow cytometry
analysis using a trypan blue (TB) assay that is based on the observation that the vital dye
TB, while quenching the FITC fluorescence of non-internalized particles causing them to
fluoresce red, it induces internalized particles to fluoresce green.[30] Flow cytometry data
showed up to 90% internalization of the EGFR-targeted Ni-NPs in the A431 cells with the
highest concentration of NPs (15 μg/mL) and longest incubation time (4 h) (Fig. 2A). ICP-
MS analysis, used to quantify cell-internalized Ni, were in good agreement with flow
cytometry results showing a dose dependent increase in Ni internalization in A431 cells
(Fig. 2B).
Cell uptake competition studies were also carried out by first incubating the cells with free
unlabeled heptameric ZEGFR domain for 30 min at various concentrations ranging from
0.035 ng/mL to 3.5 μg/mL and then adding EGFR-targeted Ni-NPs (15 μg/mL) and
incubating for an additional 4 h. The percent internalization of the targeted Ni-NPs in the
A431 cells was competed off with free heptameric ZEGFR domain concentrations of 8.75 ng/
mL or higher (Fig. 3A). It is also noteworthy that the concentration of heptameric ZEGFR
domain present in the targeted Ni-NPs when incubated at 15 μg/mL was 35 ng/mL.
Interestingly, the competition studies showed that the most significant decrease in cell
internalization of the targeted Ni-NPs occurred when the concentration of the free
heptameric ZEGFR domain exceeded 35 ng/mL (Fig. 3A). As shown in Fig. 3B, it was also
demonstrated that increasing the heptameric ZEGFR domain concentration on the surface of
the Ni-NPs, significantly enhanced the uptake of the NPs in EGFR-overexpressing A431
cells (as measured by cell internalized Ni using ICP-MS analysis).
All together, these in vitro results were very encouraging in that they demonstrated superior
cell uptake could be achieved in EGFR overexpressing cells with these Ni-NPs when
targeted with the novel heptameric ZEGFR domain.
Facilitated in vivo accumulation of EGFR-targeted Ni-NPs in EGFR+ cancer cells
Based on the results obtained from the in vitro studies, a preliminary in vivo study was
carried out to test the efficacy of the novel heptameric ZEGFR domain in targeting the new
Ni-NPs. The in vivo study was performed in female nude athymic (nu/nu) mice bearing
A431 tumors to determine the biodistribution and intracellular delivery of the EGFR-
targeted Ni-NPs. IVIS fluorescence imaging (to detect Alexa750-labeled heptameric ZEGFR
domain) and ICP-MS (to detect Ni) were both utilized to monitor untargeted and targeted
Ni-NPs. Whole-body fluorescence imaging demonstrated visible tumor accumulation of the
targeted Ni-NPs with no accumulation in the heart, lungs, stomach, intestines, or spleen
(Fig. 4). Using the same female nude athymic (nu/nu) mice, qualitative biodistribution data
were collected by harvesting the organs and tissues at 16 h post injection of untargeted and
targeted Ni-NPs via tail vein. The organs and tissues harvested from each mouse included
blood (via heart puncture), tumors, heart, lung, liver, kidneys, intestines, spleen and bladder.
Semiquantitative information was obtained by defining regions of interest (ROIs) on the
images and determining the number of counts in that volume. Fig. 5A depicts the relative
fluorescence intensity measured, normalized to the point of maximum intensity. These
results were in agreement with the whole-body images showing modest accumulation in the
liver and a stronger signal in the kidneys, presumably due to heptameric ZEGFR domain
elimination. The fluorescence intensity for EGFR-targeted Ni-NPs in the tumors was 19% of
the total detected fluorescence intensity (FI). An additional 28% FI was detected in the liver
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and 42% FI was detected in the kidneys (Table 7). In parallel to the fluorescence imaging
studies, Ni accumulation in the tumor cells was quantified by ICP-MS analysis. Tumors
were harvested 16 h post i.v. injection, and tumor cells were extracted from the tumor
homogenates and analyzed for intracellular Ni accumulation. A significant enhancement of
intracellular Ni accumulation was detected for the targeted Ni-NPs (Fig. 5B). The percent
intracellular Ni accumulation was 8% of the total injected dose (ID) of Ni, almost a two-fold
increase from untargeted Ni-NPs (5%). Collectively, these new preliminary data were very
promising and support the development of the novel heptameric ZEGFR domain to target
EGFR overexpressing cancer cells.
Conclusions
The synthesis of two new NTA-Ni conjugates was successfully accomplished with both Brij
700 and Brij 78. Using these new conjugates, Ni-NPs with high Ni incorporation (~50% and
~90% respectively) and facilitated Ni access to the surface of the NPs were prepared.
Combined, these two advantages resulted in enhanced binding efficiencies of his×6-tagged
GFP to the Ni-NPs. Interestingly, higher binding efficiencies to his×6-tagged GFP were
observed for Ni-NPs prepared with Brij 78-NTA-Ni conjugate (85% vs. 55%). These results
suggested that conjugating the NTA-Ni group to a shorter PEG chain (Brij 78 vs. Brij 700)
promoted greater protein binding via his-tag-Ni affinity interaction. The new Ni-NPs (80%
w/w Brij 78-NTA-Ni) were decorated with a novel his×6-tagged heptameric ZEGFR domain
with up to 95% binding efficiency at optimal conditions (0.002 w/w ZEGFR domain to Ni-
NPs). In vitro cell uptake studies showed up to 90% internalization of the EGFR-targeted
Ni-NPs into the EGFR overexpressing A431 cells, as compared to significantly lower uptake
(<10%) of the untargeted Ni-NPs. The targeting efficiency of the novel heptameric ZEGFR
domain was also demonstrated in vivo with almost a two-fold increase in intracellular Ni
accumulation in tumor homogenates.
To our knowledge, this is the first report on the use of a novel heptameric ZEGFR domain to
successfully target EGFR overexpressing cancer cells and the data support the development
of the novel heptameric ZEGFR domain to target EGFR overexpressing cancer cells. Future
studies will focus on translating the use of the novel heptameric ZEGFR domain to target
drug-loaded NPs to EGFR overexpressing breast cancer cells (MDA-MB-468) and EGFR
overexpressing non-small cell lung cancer cells (A549).
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SEC separation profiles using Sepharose CL-4B column. Ni-NPs eluted in fractions 5-8 as
determined by particle size intensity. Later fractions (9-15) contain micelles and unbound
heptamer. The binding efficiency of FITC-his×6-tagged-heptamer was determined by
separating NP-bound heptamer from free heptamer, which eluted in fractions 10-17 as
determined by fluorescence intensity measurements. Percent binding of FITC-his-heptamer
was determined by the percent fluorescence intensity associated with the Ni-NPs fraction.
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Cell uptake of untargeted and EGFR-targeted Ni-NPs. % internalization of NPs as a function
of dosage and incubation time. A) Flow cytometry analysis, B) ICP-MS analysis. Data in
each group represents mean ± SD (N=3, n=3).
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A) Cell uptake competition studies carried out with targeted Ni-NPs at 15 μg/20,000 cells
(with an equivalent amount of 35 ng/20,000 cells of heptameric ZEGFR domain). Incubation
time with the NPs was set to 4 h, B) Effect of heptameric ZEGFR domain concentration on
the uptake of NPs (as measured by internalized Ni concentration). Data in each group
represents mean ± SD (N=3, n=3).
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Biodistribution of heptameric EGFR-binding ZEGFR domain-targeted NPs 16 h after
intravenous injection to A431-tumor bearing nude mice. Alexa750-labeled heptameric
ZEGFR domain was used to evaluate biodistribution by optical imaging. Mice (n=4/group)
were injected with Ni-NPs with Alexa750-heptameric ZEGFR domain and Ni doses of 5.8 μg
and 178 ng, respectively. IVIS fluorescence images of (A) Naïve, (B) Untargeted Ni-NPs,
(C) Targeted Ni-NPs.
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(A) Quantitative biodistribution of Alexa750-labeled heptameric ZEGFR domain targeted Ni-
NPs (IVIS optical imaging) (* indicates p<0.05 relative to other groups), (B) Intracellular Ni
accumulation (untargeted and targeted Ni-NPs) in tumor homogenates at 16 h post i.v.
injection (ICP-MS analysis) (* indicates p<0.05 relative to other groups).
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Synthesis of Brij 700-NTA-Ni conjugate.
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Table 1
Characterization of Brij 700-NTA-Ni conjugate by ICP-MS analysis.
Sample Moles of Ni
(Theoretical)
Moles of Ni (by ICP-MS) Moles of Brij700-NTA Brij 700-NTA:Ni (by
ICP-MS)
Brij 700-NTA-Ni Unpurified 4.05 × 105 3.70 × 105 2.02 × 105 1.83
Brij 700-NTA-Ni Purified 2.02 × 105 2.06 × 105 2.02 × 105 1.02
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Table 3
Characterization of various Ni-NPs formulations.
Brij 700-NTA-Ni (Wt.%) Particle size* (nm) P.I.* Zeta potential* (mV) Ni conc., calc. (μM)
0 207 ± 1.2 0.14 ± 0.03 -5.6 ± 1.8 0
0.5 196 ± 2.9 0.13 ± 0.02 -12.4 ± 1.2 3.13
1 188 ± 1.6 0.18 ± 0.04 -17.6 ± 1.0 6.25
2 191 ± 4.3 0.28 ± 0.09 -21.8 ± 1.6 12.5
4 180 ± 4.2 0.25 ± 0.10 -20.3 ± 1.2 25.0
8 195 ± 4.0 0.29 ± 0.13 -20.9 ± 0.7 50.0
*
Data in each group represents mean ± SD (n=3).













Benhabbour et al. Page 24
Table 4
Percent Ni incorporation within the NPs using Brij 700-NTA-Ni.
Brij 700-NTA-Ni (wt.%) μg Ni Before SEC* μg Ni After SEC* % Ni incorporated*
0.5 2.73 ± 1.4 0.87 ± 0.09 32.2 ± 3.4
1 4.44 ± 2.4 1.59 ± 0.26 35.8 ± 8.4
2 11.7 ± 3.8 5.59 ± 0.53 47.8 ± 2.8
4 18.1 ± 3.6 8.07 ± 0.92 44.6 ± 4.3
8 30.8 ± 5.8 14.2 ± 2.23 46.1 ± 5.7
*
Values reflect amount of Ni per 15 mg of NPs; data in each group represents mean ± SD (n=3).
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Table 6
Optimization of his×6-tagged heptamer binding to Ni-NPs.
μg his×6-tagged heptamer† his×6-tagged heptamer:Ni-NPs ratio (w/w) %FI* μg his×6-tagged heptamer†
2.5 0.0016 92 2.3
3.5 0.002 95 3.3
5.0 0.003 81 4.1
10 0.007 84 8.4
15 0.01 83 12.5
*
Fluorescence Intensity (FI) associated with NP fractions.
†
Values reflect amount of his×6-tagged heptamer per mg of NPs.
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